Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity.

Corral, L G; Muller, G W; Moreira, A L; Chen, Y; Wu, M; Stirling, D; Kaplan, G

Corral, L G; Muller, G W; Moreira, A L; Chen, Y; Wu, M; Stirling, D; Kaplan, G.

Affiliation

Corral LG; Celgene Corporation, Warren, New Jersey, USA.

Mol Med ; 2(4): 506-15, 1996 Jul.

Article in En | MEDLINE | ID: mdl-8827720

Subject(s)

Thalidomide/analogs & derivatives; Tumor Necrosis Factor-alpha/antagonists & inhibitors; Animals; Blotting, Northern; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Humans; Interleukin-1/biosynthesis; Interleukin-10/biosynthesis; Interleukin-6/biosynthesis; Kinetics; Lipopolysaccharides/antagonists & inhibitors; Lipopolysaccharides/pharmacology; Mice; Mice, Inbred BALB C; Monocytes/drug effects; Monocytes/metabolism; RNA, Messenger/metabolism; Thalidomide/pharmacology

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thalidomide / Tumor Necrosis Factor-alpha Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Mol Med Journal subject: BIOLOGIA MOLECULAR Year: 1996 Document type: Article Affiliation country: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google